Acabrunat 100mg Capsule 30’s

Acabrunat 100mg Capsule contains Acalabrutinib, a targeted therapy used for the treatment of specific blood cancers, such as mantle cell lymphoma and chronic lymphocytic leukemia (CLL). This medication works by inhibiting Bruton’s tyrosine kinase (BTK), thereby helping to block the growth and spread of cancer cells. Acabrunat is part of a treatment plan under the supervision of a healthcare provider.

Uses:

• Effective in managing mantle cell lymphoma and chronic lymphocytic leukemia
• Helps to slow the progression of specific blood cancers by targeting and inhibiting BTK activity

Side Effects:
Common side effects include headache, fatigue, nausea, and muscle pain. Rare but serious side effects can involve changes in blood cell counts, infections, and heart-related issues. Patients are advised to consult their doctor if they experience unusual symptoms or any adverse effects.

Key Features:

• Contains Acalabrutinib 100mg, a targeted therapy for specific blood cancers
• Designed to inhibit BTK, slowing cancer cell progression
• Administered under medical supervision for optimal safety and effectiveness

FAQs:

1. What is Acabrunat 100mg used for?
   Acabrunat 100mg is prescribed to treat specific blood cancers, including chronic lymphocytic leukemia (CLL) and mantle cell lymphoma.
2. How does Acabrunat work in treating blood cancers?
   Acabrunat contains Acalabrutinib, which inhibits Bruton’s tyrosine kinase (BTK), helping to block cancer cell growth and progression.
3. What are the common side effects of Acabrunat?
   Common side effects include headache, nausea, fatigue, and muscle pain. Monitor symptoms and consult a doctor if any severe reactions occur.
4. Where can I buy Acabrunat 100mg Capsule?
   Acabrunat 100mg Capsule can be purchased from licensed pharmacies like Milan Medicals with a prescription from a healthcare provider.

References:

• AstraZeneca, Electronic Medicines Compendium (EMC), [Revised on Dec 2020], [Accessed on 5th May 2023], https://www.medicines.org.uk/emc/files/pil.11917.pdf
• AstraZeneca, US Food and Drug Administration, [Revised on Oct 2017], [Accessed on 5th May 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/210259s000lbl.pdf
• Byrd, J.C., et al. (2020). “Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.” Blood, April 2020. [Accessed on 5th May 2023]; https://pubmed.ncbi.nlm.nih.gov/31876911/